BLUE-C STUDY
TOP-LINE FINDINGS

BLUE-C is a prospective multi-center study (NCT04144738) of more than 20,000 adults 40 years of age and older. The trial was designed to evaluate the performance of our next-generation Cologuard® test (multi-target stool DNA or mt-sDNA). It is one of the largest colorectal cancer screening trials ever conducted, and the study population reflects the racial and ethnic diversity of the United States according to the 2020 census.

ABOUT THE BLUE-C STUDY

**SPECIFICITY**

Describes how well a test can correctly identify people without cancer or pre-cancer

- **91%**
  - Specificity - including non-advanced findings
  - specificity including non-advanced findings includes colonoscopy results that were negative for cancer or advanced precancer upon histopathological review

- **93%**
  - Specificity - including no findings
  - specificity including no findings includes no findings on colonoscopy and no histopathological review

**SENSITIVITY**

Describes how well a test can correctly identify people with cancer or pre-cancer

- **94%**
  - Cancer

- **75%**
  - High-grade dysplasia
  - high-grade dysplasia includes carcinoma in situ and stage 0 cancer

- **43%**
  - Advanced precancer

### Specificity

<table>
<thead>
<tr>
<th></th>
<th>Cologuard in DeeP-C study¹</th>
<th>Next-gen Cologuard in BLUE-C study²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specificity</td>
<td>87</td>
<td>91</td>
</tr>
<tr>
<td></td>
<td>including non-advanced findings</td>
<td>including no findings</td>
</tr>
<tr>
<td>Specificity</td>
<td>90</td>
<td>93</td>
</tr>
<tr>
<td></td>
<td>including no findings</td>
<td></td>
</tr>
<tr>
<td>Cancer Sensitivity</td>
<td>92</td>
<td>94</td>
</tr>
<tr>
<td>High-grade dysplasia sensitivity</td>
<td>69</td>
<td>75</td>
</tr>
<tr>
<td>Advanced precancer sensitivity</td>
<td>42</td>
<td>43</td>
</tr>
</tbody>
</table>

¹DeeP-C was the FDA registrational trial for Cologuard
3. Internal data on file. Exact Sciences Corporation. Madison, WI.